| Literature DB >> 34310208 |
Mariana Handelman1, Zohar Meir1, Jennifer Scott2, Yona Shadkchan1, Wei Liu3, Ronen Ben-Ami4, Jorge Amich2, Nir Osherov1.
Abstract
Aspergillus fumigatus is the most common cause of invasive fungal mold infections in immunocompromised individuals. Current antifungal treatment relies heavily on the triazole antifungals which inhibit fungal Erg11/Cyp51 activity and subsequent ergosterol biosynthesis. However, resistance, due primarily to cyp51 mutation, is rapidly increasing. A. fumigatus contains two Cyp51 isoenzymes, Cyp51A and Cyp51B. Overexpression and mutation of Cyp51A is a major cause of triazole resistance in A. fumigatus. The role of Cyp51B in generating resistance is unclear. Here, we show that overexpression or mutation of cyp51B results in triazole resistance. We demonstrate that introduction of a G457S Cyp51B mutation identified in a resistant clinical isolate results in voriconazole resistance in a naive recipient strain. Our results indicate that mutations in cyp51B resulting in clinical resistance do exist and should be monitored.Entities:
Keywords: Aspergillus fumigatus; azole resistance; cyp51B; drug resistance; triazole antifungals
Mesh:
Substances:
Year: 2021 PMID: 34310208 PMCID: PMC8448118 DOI: 10.1128/AAC.01252-21
Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN: 0066-4804 Impact factor: 5.191